These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 23583235)

  • 1. Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: Implications for amyloid-related imaging abnormalities.
    Zago W; Schroeter S; Guido T; Khan K; Seubert P; Yednock T; Schenk D; Gregg KM; Games D; Bard F; Kinney GG
    Alzheimers Dement; 2013 Oct; 9(5 Suppl):S105-15. PubMed ID: 23583235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-AβPPswe Mice Without Inducing Microhemorrhage.
    Villarreal S; Zhao F; Hyde LA; Holder D; Forest T; Sondey M; Chen X; Sur C; Parker EM; Kennedy ME
    J Alzheimers Dis; 2017; 59(4):1393-1413. PubMed ID: 28800329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring Blood-Brain Barrier Integrity Following Amyloid-β Immunotherapy Using Gadolinium-Enhanced MRI in a PDAPP Mouse Model.
    Blockx I; Einstein S; Guns PJ; Van Audekerke J; Guglielmetti C; Zago W; Roose D; Verhoye M; Van der Linden A; Bard F
    J Alzheimers Dis; 2016 Sep; 54(2):723-35. PubMed ID: 27567811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging detection and time course of cerebral microhemorrhages during passive immunotherapy in living amyloid precursor protein transgenic mice.
    Luo F; Rustay NR; Seifert T; Roesner B; Hradil V; Hillen H; Ebert U; Severin JM; Cox BF; Llano DA; Day M; Fox GB
    J Pharmacol Exp Ther; 2010 Dec; 335(3):580-8. PubMed ID: 20823195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy reduces vascular amyloid-beta in PDAPP mice.
    Schroeter S; Khan K; Barbour R; Doan M; Chen M; Guido T; Gill D; Basi G; Schenk D; Seubert P; Games D
    J Neurosci; 2008 Jul; 28(27):6787-93. PubMed ID: 18596154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
    Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
    Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice.
    Bard F; Fox M; Friedrich S; Seubert P; Schenk D; Kinney GG; Yednock T
    Exp Neurol; 2012 Nov; 238(1):38-43. PubMed ID: 22892246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Aβ immunotherapy for Alzheimer's disease].
    Sakai K; Yamada M
    Brain Nerve; 2013 Apr; 65(4):461-8. PubMed ID: 23568994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice.
    Demattos RB; Lu J; Tang Y; Racke MM; Delong CA; Tzaferis JA; Hole JT; Forster BM; McDonnell PC; Liu F; Kinley RD; Jordan WH; Hutton ML
    Neuron; 2012 Dec; 76(5):908-20. PubMed ID: 23217740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active Aβ vaccination fails to enhance amyloid clearance in a mouse model of Alzheimer's disease with Aβ42-driven pathology.
    Nemirovsky A; Shapiro J; Baron R; Kompaniets A; Monsonego A
    J Neuroimmunol; 2012 Jun; 247(1-2):95-9. PubMed ID: 22498096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrovascular pathology during the progression of experimental Alzheimer's disease.
    Giannoni P; Arango-Lievano M; Neves ID; Rousset MC; Baranger K; Rivera S; Jeanneteau F; Claeysen S; Marchi N
    Neurobiol Dis; 2016 Apr; 88():107-17. PubMed ID: 26774030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Traumatic brain injury in young, amyloid-beta peptide overexpressing transgenic mice induces marked ipsilateral hippocampal atrophy and diminished Abeta deposition during aging.
    Nakagawa Y; Nakamura M; McIntosh TK; Rodriguez A; Berlin JA; Smith DH; Saatman KE; Raghupathi R; Clemens J; Saido TC; Schmidt ML; Lee VM; Trojanowski JQ
    J Comp Neurol; 1999 Aug; 411(3):390-8. PubMed ID: 10413774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.
    Adolfsson O; Pihlgren M; Toni N; Varisco Y; Buccarello AL; Antoniello K; Lohmann S; Piorkowska K; Gafner V; Atwal JK; Maloney J; Chen M; Gogineni A; Weimer RM; Mortensen DL; Friesenhahn M; Ho C; Paul R; Pfeifer A; Muhs A; Watts RJ
    J Neurosci; 2012 Jul; 32(28):9677-89. PubMed ID: 22787053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
    Rakover I; Arbel M; Solomon B
    Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?
    Tayeb HO; Murray ED; Price BH; Tarazi FI
    Expert Opin Biol Ther; 2013 Jul; 13(7):1075-84. PubMed ID: 23574434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced Efficacy of Anti-Aβ Immunotherapy in a Mouse Model of Amyloid Deposition and Vascular Cognitive Impairment Comorbidity.
    Weekman EM; Sudduth TL; Caverly CN; Kopper TJ; Phillips OW; Powell DK; Wilcock DM
    J Neurosci; 2016 Sep; 36(38):9896-907. PubMed ID: 27656027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular amyloid-β accumulation in calcium-binding protein-deficient neurons leads to amyloid-β plaque formation in animal model of Alzheimer's disease.
    Moon M; Hong HS; Nam DW; Baik SH; Song H; Kook SY; Kim YS; Lee J; Mook-Jung I
    J Alzheimers Dis; 2012; 29(3):615-28. PubMed ID: 22269161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage.
    Burbach GJ; Vlachos A; Ghebremedhin E; Del Turco D; Coomaraswamy J; Staufenbiel M; Jucker M; Deller T
    Neurobiol Aging; 2007 Feb; 28(2):202-12. PubMed ID: 16427722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease.
    Chauhan NB; Siegel GJ
    Expert Rev Vaccines; 2004 Dec; 3(6):717-25. PubMed ID: 15606357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.